Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SMRP



This biomarker is also known as:
  • MSLN,
  • Soluble Mesothelin Related Peptide,

View in BioMuta


Soluble mesothelin-related protein (SMRP) is related to the mesothelin family of molecules. It is overexpressed in ovarian cancer, malignant pleural mesothelioma (MPM), and certain other cancers. One hypothesis for the origin of SMRP is that this mesothelin-like molecule was released from tumor cells into culture supernatants, sera, and malignant effusions from certain tumors. Another hypothesis is that SMRP is actually a proteolytically cleaved fragment of membrane-bound mesothelin. Currently SMRP is considered to be an isoform of mesothelin (MSLN). UniprotKB/SwissProt lists isoform 3 of human mesothelin (identifier Q13421-2) as SMRP.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Differentially expressed mesothelial protein. May comprise a biomarker panel with SPP1 (osteopontin). SMRP can be assayed using MESOMARK, a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve. The MESOMARK assay may be useful for the detection and management of mesothelioma.

Performance Comment

SMRP is a promising biomarker for malignant pleural mesothelioma (MPM) in both serum and pleural effusion fluid.



Phase: Two
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.